While chronic obstructive pulmonary disease (COPD) is still characterized and diagnosed by lung function measurements, there is increasing evidence that the chronic diseases that frequently develop with COPD in response to the common risk factors (smoking, aging, obesity) may contribute significantly to its clinical manifestations and severity. Considering that pharmacologic and nonpharmacologic treatments of COPD, such as pulmonary rehabilitation, are primarily symptomatic, it is reasonable to hope that a more comprehensive management of COPD that takes into account its comorbidities may improve the response to treatment and reduce mortality in patients with COPD. Thus, as comorbidities are often underdiagnosed and undertreated, it is important to search for their coexistence in COPD and in all chronic diseases, possibly by adopting recommendations for diagnosis of single diseases. This means that while careful cardiovascular, metabolic, and endocrinologic examinations should be increasingly used in assessing patients with COPD, lung function measurements may become useful in patients with chronic cardiovalscular, metabolic, and endocrinologic diseases. The increasing evidence that active treatment of comorbidities (by, e.g., statins and beta-blockers) may reduce morbidity and mortality in patients with COPD suggests the urgent need for randomized clinical trials that hopefully will provide the evidence for more comprehensive clinical guidelines for these patients.

Treatment of chronic obstructive pulmonary disease and its comorbidities / Luppi, Fabrizio; Franco, F; Beghe', Bianca; Fabbri, Leonardo. - In: PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY. - ISSN 1546-3222. - STAMPA. - 5:8(2008), pp. 848-856. [10.1513/pats.200809-101TH]

Treatment of chronic obstructive pulmonary disease and its comorbidities

LUPPI, Fabrizio;BEGHE', Bianca;FABBRI, Leonardo
2008

Abstract

While chronic obstructive pulmonary disease (COPD) is still characterized and diagnosed by lung function measurements, there is increasing evidence that the chronic diseases that frequently develop with COPD in response to the common risk factors (smoking, aging, obesity) may contribute significantly to its clinical manifestations and severity. Considering that pharmacologic and nonpharmacologic treatments of COPD, such as pulmonary rehabilitation, are primarily symptomatic, it is reasonable to hope that a more comprehensive management of COPD that takes into account its comorbidities may improve the response to treatment and reduce mortality in patients with COPD. Thus, as comorbidities are often underdiagnosed and undertreated, it is important to search for their coexistence in COPD and in all chronic diseases, possibly by adopting recommendations for diagnosis of single diseases. This means that while careful cardiovascular, metabolic, and endocrinologic examinations should be increasingly used in assessing patients with COPD, lung function measurements may become useful in patients with chronic cardiovalscular, metabolic, and endocrinologic diseases. The increasing evidence that active treatment of comorbidities (by, e.g., statins and beta-blockers) may reduce morbidity and mortality in patients with COPD suggests the urgent need for randomized clinical trials that hopefully will provide the evidence for more comprehensive clinical guidelines for these patients.
2008
5
848
856
Luppi, Fabrizio; Franco, F; Beghe', Bianca; Fabbri, Leonardo
Treatment of chronic obstructive pulmonary disease and its comorbidities / Luppi, Fabrizio; Franco, F; Beghe', Bianca; Fabbri, Leonardo. - In: PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY. - ISSN 1546-3222. - STAMPA. - 5:8(2008), pp. 848-856. [10.1513/pats.200809-101TH]
File in questo prodotto:
File Dimensione Formato  
Pats_COPD_2008.pdf

Solo gestori archivio

Tipologia: Versione pubblicata dall'editore
Dimensione 527.93 kB
Formato Adobe PDF
527.93 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/593611
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 48
  • ???jsp.display-item.citation.isi??? ND
social impact